CEL-SCI Corp (CVM)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.63+1.24%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduction in net loss per share: metric not reported.
CEL-SCI formed a strategic partnership with Amarox to commercialize Multikine in Saudi Arabia and GCC. The company raised $7.2 million in an equity offering in 2026-Q2 to support operations. These moves advance its cancer drug development. If the drug succeeds, it could generate future revenue.
CEL-SCI remains loss-making with a mean EPS of -$4.16 in 2026 and -$0.92 in 2027. The company has no revenue estimates and continues to rely on equity offerings. Its financial losses and lack of sales raise doubts about sustainable growth.
The market prices in continued losses and no revenue growth, reflected by negative EPS estimates through 2027. Our view differs by focusing on the potential upside from the Amarox partnership and equity raise, but the risk remains high given ongoing losses.
Breaks if: EPS does not improve or worsens beyond -$0.92 in FY27
Breaks if: Equity offering raises less than $7.2 million or fails to close by 2026-Q2
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CVM represents a speculative growth investment with a focus on developing its Multikine product. The current thesis state is cautious, as the company is navigating significant operational losses and a high-risk environment.
The market appears to have priced in a challenging outlook, given the company's loss-making status and high risk label. There is an expectation that the healthcare sector's performance will influence CVM's trajectory, particularly in relation to sector leaders.
Fundamentals are likely to remain under pressure due to ongoing operating losses and negative cash flow. Management's efforts to raise capital through equity offerings indicate a need for sustained funding to support operations and development.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, which could either support or hinder CVM's growth. Additionally, the success of the strategic partnership with Amarox for Multikine commercialization will be critical.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Conduct an equity offering to raise $7.2 million in gross proceeds.
Breaks if: Partnership fails to advance regulatory or marketing milestones by end 2026
Form a strategic partnership with Amarox for Multikine commercialization in Saudi Arabia and potentially GCC countries.
In the next 1 to 3 years, CVM's outlook will depend on its ability to manage losses and capitalize on sector trends. Not investment advice.